Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK plus NSCLC): Primary Results from Phase III Study (J-ALEX)

被引：5

作者：

Kim, Young ^{[1
]}

Hida, Toyoaki ^{[2
]}

Nokihara, Hiroshi ^{[3
]}

Kondo, Masashi ^{[4
]}

Azuma, Koichi ^{[5
]}

Seto, Takashi ^{[6
]}

Takiguchi, Yuichi ^{[7
]}

Nishio, Makoto ^{[8
]}

Yoshioka, Hiroshige ^{[9
]}

Imamura, Fumio ^{[10
]}

Hotta, Katsuyuki ^{[11
]}

Watanabe, Satoshi ^{[12
]}

Goto, Koichi ^{[13
]}

Nakagawa, Kazuhiko ^{[14
]}

Mitsudomi, Tetsuya ^{[15
]}

Yamamoto, Nobuyuki ^{[16
]}

Kuriki, Hiroshi ^{[17
]}

Asabe, Ryoichi ^{[17
]}

Tanaka, Tomohiro ^{[18
]}

Tamura, Tomohide ^{[19
]}

机构：

[1] Kyoto Univ, Kyoto, Japan

[2] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[3] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[4] Nagoya Univ, Resp Med, Nagoya, Aichi, Japan

[5] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka, Japan

[6] Natl Kyushu Canc Ctr, Fukuoka, Japan

[7] Chiba Univ, Grad Sch Med, Dept Med Oncol, Chiba, Japan

[8] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan

[9] Kurashiki Cent Hosp, Kurashiki, Okayama, Japan

[10] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan

[11] Okayama Univ Hosp, Okayama, Japan

[12] Osaka Med Ctr Canc & Cardiovasc Dis, Niigata, Japan

[13] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Chiba, Japan

[14] Kindai Univ, Fac Med, Osaka, Japan

[15] Kindai Univ, Fac Med, Dept Surg, Div Thorac Surg, Osaka, Japan

[16] Wakayama Med Univ, Internal Med, Wakayama, Japan

[17] Chugai Pharmaceut Co Ltd, Tokyo, Japan

[18] Chugai Pharmaceut Co Ltd, Clin Sci & Strategy Dept, Tokyo, Japan

[19] St LukeS Int Hosp, Tokyo, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

ALK Inhibitor; ALK plus NSCLC;

D O I：

10.1016/j.jtho.2016.11.427

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA07.03

引用

页码：S378 / S379

页数：2

共 50 条

[41] Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases
Lockney, Natalie A.
Wu, Abraham J.
JOURNAL OF THORACIC DISEASE, 2017, 9 (02) : E152 - E154
[42] ALECTINIB FOR THE TREATMENT OF ALK-POSITIVE STAGE IV NON-SMALL CELL LUNG CANCER
Wong, K. M.
Noonan, S.
O'Bryant, C.
Jimeno, A.
DRUGS OF TODAY, 2015, 51 (03) : 161 - 170
[43] Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer
Koizumi, Tomonobu
Fukushima, Toshirou
Tatai, Toshiharu
Kobayashi, Takashi
Sekiguchi, Nodoka
Sakamoto, Akiyuki
Sasaki, Shigeru
LUNG CANCER, 2015, 88 (01) : 112 - 113
[44] Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
Karachaliou, Niki
Fernandez Bruno, Manuel
Paulina Bracht, Jillian Wilhelmina
Rosell, Rafael
ONCOTARGETS AND THERAPY, 2019, 12 : 4567 - 4575
[45] Final Progression-Free Survival (PFS), Updated Overall Survival (OS), And Safety Data from the Global, Randomized, Phase 3 Alex Study of Alectinib (ALC) Versus Crizotinib (CRZ) in Untreated Advanced ALK plus Non-Small Cell Lung Cancer (NSCLC)
Hoffknecht, Petra
Mok, Tony
Shaw, Alice I.
Camidge, D. Ross
Gadgeel, Shirish
Rosell, Rafael
Dziadziuszko, Rafal
Kim, Dong-Wan
Perol, Maurice
Ou, Sai-Hong
Bordogna, Walter
Smoljanovic, Vlatka
Hilton, Magalie
Peters, Solange
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 236 - 236
[46] Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
Morcos, Peter N.
Nueesch, Eveline
Jaminion, Felix
Guerini, Elena
Hsu, Joy C.
Bordogna, Walter
Balas, Bogdana
Mercier, Francois
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 129 - 138
[47] Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Nishio, Makoto
Kim, Dong-Wan
Wu, Yi-Long
Nakagawa, Kazuhiko
Solomon, Benjamin J.
Shaw, Alice T.
Hashigaki, Satoshi
Ohki, Emiko
Usari, Tiziana
Paolini, Jolanda
Polli, Anna
Wilner, Keith D.
Mok, Tony
CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 691 - 700
[48] Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer
Toffart, A. -C.
Sakhri, L.
Moro-Sibilot, D.
REVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (02) : 111 - 116
[49] ESTIMATING THE BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ARGENTINA
Wang, B.
Furnback, W.
Xuan, J.
VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
[50] CLINICAL EXPERIENCE WITH CRIZOTINIB IN SPECIAL POPULATIONS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
Ahn, M-J
Crino, L.
Solomon, Ben
Zhou, Caicun
Ou, Sai-hong I.
Selaru, P.
Cohen, D. P.
Bartlett, C. H.
Kim, Dong-wan
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S490 - S491

← 1 2 3 4 5 →